Real-world study shows SGLT-2i does not affect cancer rates in individuals with type 2 diabetes, suggesting further exploration is needed.
In this large real-world study of individuals with T2D, initiation of SGLT-2i was not associated with higher or lower rates of OAC compared with DPP-4i. However, initiation of SGLT-2i was associated with a modestly lower rate of the all-cancer outcome, the clinical significance of which remains unclear.
No takes yet. Share an insight, caveat, or question.
Ipaye et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: